265 related articles for article (PubMed ID: 15972965)
1. Biological role of anaplastic lymphoma kinase in neuroblastoma.
Osajima-Hakomori Y; Miyake I; Ohira M; Nakagawara A; Nakagawa A; Sakai R
Am J Pathol; 2005 Jul; 167(1):213-22. PubMed ID: 15972965
[TBL] [Abstract][Full Text] [Related]
2. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines.
Miyake I; Hakomori Y; Shinohara A; Gamou T; Saito M; Iwamatsu A; Sakai R
Oncogene; 2002 Aug; 21(38):5823-34. PubMed ID: 12185581
[TBL] [Abstract][Full Text] [Related]
3. Domain-specific function of ShcC docking protein in neuroblastoma cells.
Miyake I; Hakomori Y; Misu Y; Nakadate H; Matsuura N; Sakamoto M; Sakai R
Oncogene; 2005 Apr; 24(19):3206-15. PubMed ID: 15735675
[TBL] [Abstract][Full Text] [Related]
4. Expression of the ALK tyrosine kinase gene in neuroblastoma.
Lamant L; Pulford K; Bischof D; Morris SW; Mason DY; Delsol G; Mariamé B
Am J Pathol; 2000 May; 156(5):1711-21. PubMed ID: 10793082
[TBL] [Abstract][Full Text] [Related]
5. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK.
Futami H; Sakai R
Cancer Lett; 2010 Nov; 297(2):220-5. PubMed ID: 20576349
[TBL] [Abstract][Full Text] [Related]
8. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth.
Motegi A; Fujimoto J; Kotani M; Sakuraba H; Yamamoto T
J Cell Sci; 2004 Jul; 117(Pt 15):3319-29. PubMed ID: 15226403
[TBL] [Abstract][Full Text] [Related]
9. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines.
Dirks WG; Fähnrich S; Lis Y; Becker E; MacLeod RA; Drexler HG
Int J Cancer; 2002 Jul; 100(1):49-56. PubMed ID: 12115586
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
11. Distinct role of ShcC docking protein in the differentiation of neuroblastoma.
Miyake I; Ohira M; Nakagawara A; Sakai R
Oncogene; 2009 Feb; 28(5):662-73. PubMed ID: 18997821
[TBL] [Abstract][Full Text] [Related]
12. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
13. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
[TBL] [Abstract][Full Text] [Related]
14. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I; Lequin D; Brugières L; Ribeiro A; de Pontual L; Combaret V; Raynal V; Puisieux A; Schleiermacher G; Pierron G; Valteau-Couanet D; Frebourg T; Michon J; Lyonnet S; Amiel J; Delattre O
Nature; 2008 Oct; 455(7215):967-70. PubMed ID: 18923523
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
[TBL] [Abstract][Full Text] [Related]
16. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
Okubo J; Takita J; Chen Y; Oki K; Nishimura R; Kato M; Sanada M; Hiwatari M; Hayashi Y; Igarashi T; Ogawa S
Oncogene; 2012 Nov; 31(44):4667-76. PubMed ID: 22249260
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
19. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
[TBL] [Abstract][Full Text] [Related]
20. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.
Piva R; Pellegrino E; Mattioli M; Agnelli L; Lombardi L; Boccalatte F; Costa G; Ruggeri BA; Cheng M; Chiarle R; Palestro G; Neri A; Inghirami G
J Clin Invest; 2006 Dec; 116(12):3171-82. PubMed ID: 17111047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
